Invesco’s Rigel Pharmaceuticals RIGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $782K | Sell |
28,937
-5,984
| -17% | -$201K | ﹤0.01% | 2973 |
|
|
2025
Q4 | $1.5M | Buy |
34,921
+6,790
| +24% | +$256K | ﹤0.01% | 2739 |
|
|
2025
Q3 | $797K | Buy |
28,131
+7,796
| +38% | +$233K | ﹤0.01% | 3029 |
|
|
2025
Q2 | $381K | Sell |
20,335
-113,737
| -85% | -$2.16M | ﹤0.01% | 3279 |
|
|
2025
Q1 | $2.41M | Buy |
+134,072
| New | +$2.72M | ﹤0.01% | 2470 |
|
|
2024
Q4 | – | Sell |
-1,051,355
| Closed | -$17M | – | 3807 |
|
|
2024
Q3 | $17M | Buy |
1,051,355
+1,032,755
| +5,552% | +$12.1M | ﹤0.01% | 1548 |
|
|
2024
Q2 | $153K | Buy |
18,600
+10,050
| +118% | +$105K | ﹤0.01% | 3691 |
|
|
2024
Q1 | $127K | Buy |
8,550
+103
| +1% | +$1.39K | ﹤0.01% | 3721 |
|
|
2023
Q4 | $122K | Sell |
8,447
-860
| -9% | -$8.79K | ﹤0.01% | 3660 |
|
|
2023
Q3 | $101K | Buy |
9,307
+527
| +6% | +$6.34K | ﹤0.01% | 3719 |
|
|
2023
Q2 | $113K | Buy |
8,780
+426
| +5% | +$5.76K | ﹤0.01% | 3707 |
|
|
2023
Q1 | $110K | Sell |
8,354
-8,596
| -51% | -$137K | ﹤0.01% | 3696 |
|
|
2022
Q4 | $254K | Sell |
16,950
-499,891
| -97% | -$4.58M | ﹤0.01% | 3586 |
|
|
2022
Q3 | $6.1M | Buy |
516,841
+854
| +0.2% | +$11.6K | ﹤0.01% | 2112 |
|
|
2022
Q2 | $5.83M | Sell |
515,987
-185
| -0% | -$3.71K | ﹤0.01% | 2203 |
|
|
2022
Q1 | $15.4M | Sell |
516,172
-48
| -0% | -$1.3K | ﹤0.01% | 1678 |
|
|
2021
Q4 | $13.7M | Sell |
516,220
-1,875
| -0.4% | -$56.6K | ﹤0.01% | 1809 |
|
|
2021
Q3 | $18.8M | Buy |
518,095
+1,619
| +0.3% | +$63.7K | ﹤0.01% | 1607 |
|
|
2021
Q2 | $22.4M | Buy |
516,476
+2,383
| +0.5% | +$90K | 0.01% | 1543 |
|
|
2021
Q1 | $17.6M | Buy |
514,093
+1,434
| +0.3% | +$56.8K | ﹤0.01% | 1624 |
|
|
2020
Q4 | $17.9M | Buy |
512,659
+11,435
| +2% | +$331K | 0.01% | 1489 |
|
|
2020
Q3 | $12M | Buy |
501,224
+48
| +0% | +$1.18K | ﹤0.01% | 1565 |
|
|
2020
Q2 | $9.17M | Buy |
501,176
+6
| +0% | +$108 | ﹤0.01% | 1680 |
|
|
2020
Q1 | $7.82M | Buy |
501,170
+1,157
| +0.2% | +$24.6K | ﹤0.01% | 1645 |
|
|
2019
Q4 | $10.7M | Hold |
500,013
| – | – | ﹤0.01% | 1725 |
|
|
2019
Q3 | $9.35M | Hold |
500,013
| – | – | ﹤0.01% | 1776 |
|
|
2019
Q2 | $13.1M | Buy |
+500,013
| New | +$11.3M | ﹤0.01% | 1638 |
|
|
2018
Q2 | – | Sell |
-1,169
| Closed | -$41K | – | 3911 |
|
|
2018
Q1 | $41K | Buy |
1,169
+107
| +10% | +$4.28K | ﹤0.01% | 3699 |
|
|
2017
Q4 | $41K | Sell |
1,062
-98
| -8% | -$3.73K | ﹤0.01% | 3635 |
|
|
2017
Q3 | $29K | Buy |
1,160
+49
| +4% | +$1.19K | ﹤0.01% | 3642 |
|
|
2017
Q2 | $30K | Buy |
+1,111
| New | +$30.4K | ﹤0.01% | 3677 |
|
|
2016
Q3 | – | Sell |
-3,641
| Closed | -$81K | – | 3676 |
|
|
2016
Q2 | $81K | Sell |
3,641
-1,832
| -33% | -$45.6K | ﹤0.01% | 3636 |
|
|
2016
Q1 | $114K | Sell |
5,473
-3,826
| -41% | -$94.4K | ﹤0.01% | 3635 |
|
|
2015
Q4 | $282K | Buy |
9,299
+161
| +2% | +$4.88K | ﹤0.01% | 3465 |
|
|
2015
Q3 | $225K | Buy |
9,138
+170
| +2% | +$5.07K | ﹤0.01% | 3536 |
|
|
2015
Q2 | $288K | Buy |
8,968
+3,597
| +67% | +$137K | ﹤0.01% | 3593 |
|
|
2015
Q1 | $192K | Sell |
5,371
-935
| -15% | -$25.6K | ﹤0.01% | 3700 |
|
|
2014
Q4 | $143K | Buy |
6,306
+322
| +5% | +$6.51K | ﹤0.01% | 3728 |
|
|
2014
Q3 | $116K | Buy |
5,984
+321
| +6% | +$9.07K | ﹤0.01% | 3805 |
|
|
2014
Q2 | $206K | Sell |
5,663
-50
| -0.9% | -$1.7K | ﹤0.01% | 3685 |
|
|
2014
Q1 | $222K | Buy |
5,713
+3,770
| +194% | +$134K | ﹤0.01% | 3694 |
|
|
2013
Q4 | $55K | Buy |
1,943
+144
| +8% | +$4.23K | ﹤0.01% | 4084 |
|
|
2013
Q3 | $64K | Buy |
1,799
+184
| +11% | +$6.71K | ﹤0.01% | 4056 |
|
|
2013
Q2 | $54K | Buy |
+1,615
| New | +$73.2K | ﹤0.01% | 4044 |
|
Other funds holding RIGL
AC
VCM
Invesco's RIGL Position: Q1 2026 in Review
Invesco reduced its Rigel Pharmaceuticals (RIGL) stake by 17% in Q1 2026, selling an estimated $201K and leaving 28,937 shares worth $782K. The position accounts for ﹤0.01% of the portfolio, ranked #2973.
Invesco first reported a position in RIGL in Q2 2013 and has held it in 44 quarters since. The position peaked at $22.4M in Q2 2021. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.
- Invesco held 28,937 shares of Rigel Pharmaceuticals worth $782K as of Q1 2026.
- Invesco sold 5,984 Rigel Pharmaceuticals shares in Q1 2026, an estimated $201K.
- Rigel Pharmaceuticals made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #2973 holding.
- Invesco first reported a position in Rigel Pharmaceuticals in Q2 2013 and has held it in 44 quarters since.
- Invesco's Rigel Pharmaceuticals position peaked at $22.4M in Q2 2021.
- 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.
Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.